Resiliva 80 mg

This is timely — semaglutide actually became the second FDA-approved MASH treatment since I last researched this drug, which changes the comparison meaningfully. These two drugs work through genuinely different mechanisms and bring different strengths to the table.

Two different approval timelines, same fibrosis population

Fundamentally different mechanisms — direct liver action vs. systemic metabolic effect

Resmetirom primarily targets hepatic lipid disposal, whereas semaglutide unloads systemic caloric pressure — this is the conceptual heart of the comparison. Resmetirom works directly inside liver cells, activating THR-β to increase fat breakdown specifically in the liver. Semaglutide works through an entirely different, body-wide pathway: it’s a GLP-1 receptor agonist that reduces appetite and caloric intake, producing substantial weight loss that, in turn, indirectly benefits the liver.

Post-hoc analyses revealed that patients who lost more than 10% body weight experienced greater fibrosis regression, supporting the idea that weight loss, rather than a direct antifibrotic mechanism, plays the central role in histologic repair with GLP-1 therapy. This is a meaningfully different therapeutic logic than resmetirom’s direct, liver-targeted approach.

Efficacy — both show real histologic benefit, broadly in a similar range

In the ESSENCE phase 3 trial, the combined endpoint of both steatohepatitis resolution and at least one stage of fibrosis improvement was achieved by 32.8% of semaglutide-treated patients versus 16.2% with placebo. This came alongside substantial weight reduction — a mean change of -10.5% with semaglutide versus -2.0% with placebo.

This is comparable in magnitude to resmetirom’s MAESTRO-NASH results we covered on the product page (24-30% achieving the primary endpoints versus 10-14% placebo) — both drugs clear a similar bar of meaningful, statistically significant histologic benefit over placebo, though they aren’t from a head-to-head trial against each other.

A key practical finding — they may work even better together

A prespecified analysis of MAESTRO-NASH specifically examined resmetirom’s effects in patients who were already on stable background GLP-1 receptor agonist or SGLT2 inhibitor therapy and found resmetirom maintained consistent benefit regardless of this background treatment. Notably, achieving at least 5% weight loss enhanced resmetirom’s efficacy for both MASH resolution and fibrosis improvement, suggesting a complementary rather than competing mechanism between the two drug classes.

This is echoed directly by clinical experts: some patients will have an initial response to GLP-1 therapy but may still experience progressive disease over time, at which point resmetirom could be added on top of GLP-1 therapy — meaning these increasingly look like sequential or combination options rather than strictly either-or competitors.

Tolerability — this is where the practical difference is most pronounced

Tolerability issues and insurance coverage challenges lead to 20-30% of patients discontinuing GLP-1 therapy — a substantial real-world dropout rate driven by the well-known GLP-1 side effects (nausea, vomiting, and gastrointestinal symptoms during dose escalation). Many patients who don’t tolerate the GLP-1 medication can be switched to resmetirom instead, according to clinical opinion — positioning resmetirom partly as a fallback for GLP-1-intolerant patients, similar in spirit to how we’ve discussed drug-switching strategies for side-effect intolerance elsewhere in this conversation.

Cardiovascular benefit — a genuine advantage unique to semaglutide

Semaglutide’s impact on cardiovascular outcomes has been confirmed in large trials for diabetes and obesity, where major adverse cardiovascular events were reduced by 21-26%. Since cardiovascular disease is the leading cause of death in MASH patients, this additional benefit could be clinically crucial even if semaglutide’s direct effect on liver fibrosis is somewhat slower or more modest than other medications. This is a meaningful point: resmetirom’s benefit is essentially liver-confined, while semaglutide offers a broader cardiometabolic benefit that directly addresses what’s often the bigger overall mortality risk in this patient population.

Cost-effectiveness — recent modeling favors semaglutide

A cost-effectiveness analysis comparing semaglutide and resmetirom against standard of care in noncirrhotic MASH with F2-F3 fibrosis found semaglutide demonstrated superior cost-effectiveness compared with both standard of care and resmetirom, with semaglutide’s cardiovascular mortality benefit further strengthening its economic value. This is a notable finding, since GLP-1 medications are often perceived as expensive — but when cardiovascular benefit is factored into the broader health-economic picture, the analysis favored semaglutide.

Where the field appears to be heading

Future goals in this field include improving efficacy and tolerability, and potentially combining treatments like resmetirom and GLP-1 therapy for enhanced outcomes, with long-term cardiovascular benefits expected to make GLP-1s a valuable addition to MASH treatment strategies — strongly suggesting that the future of MASH treatment isn’t necessarily “pick one,” but increasingly “use both, sequentially or together,” matched to what the individual patient needs and tolerates.

Bottom line

Resmetirom and semaglutide aren’t strictly competing options — they work through different mechanisms (direct hepatic lipid metabolism versus systemic weight loss and metabolic improvement) and appear to provide complementary, not redundant, benefit when used together. Resmetirom offers a once-daily oral option with a liver-specific mechanism and a reasonable fallback when GLP-1 intolerance is the issue; semaglutide offers substantial weight loss, possible superior cost-effectiveness when cardiovascular benefit is included, and protection against the cardiovascular disease that’s often the leading cause of death in this patient population, but comes with a meaningfully higher real-world discontinuation rate due to tolerability. For a patient with MASH and significant fibrosis, particularly one who also has obesity, type 2 diabetes, or elevated cardiovascular risk, this is exactly the kind of decision where a hepatologist working alongside an endocrinologist or your primary care physician can help weigh whether one, the other, or a combination approach fits your overall metabolic picture best.